Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of VXCO-100 in Healthy Adults in the United States

NCT05870839 is registered in ClinicalTrials.gov with Vaccine Company, Inc. as lead sponsor.

NCT NCT05870839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05870839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of VXCO-100 in Healthy Adults in the United States
Lead sponsor
Vaccine Company, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 11, 2023
Completion date
April 10, 2024
Enrollment
121 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov, sars-cov-2